Cape Argus reports on PrEPVacc study application

The Cape Argus in South Africa has reported on PrEPVacc’s application for regulatory approval to begin its clinical studies in the country.

Following the application to the SA Health Products Regulation Authority, PrEPVacc country PI for South Africa, Professor Glenda Gray told the newspaper that PrEPVacc was a very efficient way of doing an HIV-prevention trial:

“It’s actually testing two different ways of preventing HIV at the same time. There are the two different vaccine combinations being trialled and a preventive oral medicine known as PrEP that participants will be offered.”

Professor Gray, who is SA Medical Research Council president and chief executive, noted that there were already two large-scale HIV vaccine trials underway in Africa and that if PrEPVacc’s application was successful it would be the third active HIV vaccination trial in the region.

“All the countries taking part in PrEPVacc are committed to reducing and ultimately stopping all new HIV infections, and a successful HIV vaccine is crucial for prevention.”

Read the full story here: https://www.iol.co.za/capeargus/news/new-hiv-vaccine-could-soon-be-clinically-tested-in-sa-41428704